Imbalance of endogenous prostanoids in moderate-to-severe asthma

被引:7
|
作者
Takemura, Masaya [1 ]
Niimi, Akio [1 ,2 ]
Matsumoto, Hisako [1 ]
Ueda, Tetsuya [1 ]
Yamaguchi, Masafumi [1 ]
Matsuoka, Hirofumi [1 ]
Jinnai, Makiko [1 ]
Chung, Kian Fan [3 ]
Mishima, Michiaki [1 ]
机构
[1] Kyoto Univ, Dept Resp Med, Kyoto, Japan
[2] Nagoya City Univ, Sch Med Sci, Dept Resp Med Allergy & Clin Immunol, Nagoya, Aichi, Japan
[3] Imperial Coll, Natl Heart & Lung Inst, Thorac Med, London, England
关键词
Asthma; Epithelial damage; Induced sputum; Prostaglandin; Thromboxane; BRONCHIAL SMOOTH-MUSCLE; ASPIRIN-INDUCED ASTHMA; AIRWAY INFLAMMATION; PROSTAGLANDIN D-2; EICOSANOID CONCENTRATIONS; ALVEOLAR MACROPHAGES; INDUCED CONTRACTION; RECEPTOR SUBTYPE; EP4; RECEPTOR; MILD ASTHMA;
D O I
10.1016/j.alit.2016.05.013
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Inhalation studies suggested "protective" roles of exogenous prostaglandin E-2, but the clinical relevance of endogenous prostanoids in asthma is poorly known. The objective of this study is to measure sputum levels of prostanoids in asthmatic patients to correlate with clinical indices. Methods: Mild (n = 41) or moderate-to-severe (19) asthmatics and 27 normal controls were examined for pulmonary function (FEV1 and mid-forced expiratory flow), sputum cell differentials, and sputum levels of prostaglandins D-2, E-2, F-2 alpha, and thromboxane B-2 measured by sandwich enzyme immunoassay. Results: Each prostanoid level did not differ among the three groups. Sputum number of bronchial epithelial cells was greater in moderate-to-severe asthmatics than in the other two groups, suggesting epithelial desquamation. Levels of prostaglandin F-2 alpha, D-2, and thromboxane B-2 positively correlated with the severity of airflow obstruction in the 60 asthmatic patients, whereas prostaglandin E-2 levels were unrelated to pulmonary function. The ratio of combined "contractile" prostanoids (prostaglandin D-2/prostaglandin F-2 alpha/thromboxane B-2) to prostaglandin E-2 was 2.5-fold greater in moderate-to-severe asthmatics than in controls (p = 0.001) or in mild asthmatics (p = 0.0002) but did not differ between the latter two groups. In the two asthmatic groups combined, this ratio positively correlated with the sputum number of epithelial cells. The combined "contractile" prostanoids levels positively correlated with prostaglandin E-2 levels in controls and in mild asthmatics but not in moderate-to-severe asthmatics. Conclusions: An imbalance in production, breakdown, or both between prostaglandin E-2 and other prostanoids possibly due to epithelial damage may be involved in the pathogenesis of moderate-to severe asthma. Copyright (C) 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V.
引用
收藏
页码:83 / 88
页数:6
相关论文
共 50 条
  • [41] An ATLAS of Cytokine Profiles and Associated Clinical Features in Moderate-to-Severe Asthma
    Nopsopon, Tanawin
    Brodeur, Kailey
    Lee, Pui
    Weiss, Scott
    Akenroye, Ayobami
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (02)
  • [42] Adoption and implementation of maintenance and reliever therapy for adults with moderate-to-severe asthma
    Zaeh, Sandra E.
    Zimmerman, Zoe E.
    Eakin, Michelle N.
    Chupp, Geoffrey
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (03) : 318 - 324
  • [43] Clinical Response Predictive Model for Omalizumab in Moderate-to-Severe Asthma Patients
    Qian, Ruiqi
    Yang, Lingyi
    Shen, Xurui
    Chen, Cheng
    Huang, Jianan
    Zhang, Xiuqin
    Fu, Cuiping
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 2024
  • [44] Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial
    Holgate, S. T.
    Noonan, M.
    Chanez, P.
    Busse, W.
    Dupont, L.
    Pavord, I.
    Hakulinen, A.
    Paolozzi, L.
    Wajdula, J.
    Zang, C.
    Nelson, H.
    Raible, D.
    EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (06) : 1352 - 1359
  • [45] Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma
    Papi, Alberto
    Castro, Mario
    Corren, Jonathan
    Pavord, Ian D.
    Tohda, Yuji
    Altincatal, Arman
    Pandit-Abid, Nami
    Laws, Elizabeth
    Akinlade, Bolanle
    Mannent, Leda P.
    Gall, Rebecca
    Jacob-Nara, Juby A.
    Deniz, Yamo
    Rowe, Paul J.
    Lederer, David J.
    Hardin, Megan
    RESPIRATORY MEDICINE, 2024, 224
  • [46] Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab
    Long, Aidan
    Rahmaoui, Abdelkader
    Rothman, Kenneth J.
    Guinan, Eva
    Eisner, Mark
    Bradley, Mary S.
    Iribarren, Carlos
    Chen, Hubert
    Carrigan, Gillis
    Rosen, Karin
    Szefler, Stanley J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 134 (03) : 560 - +
  • [47] Efficacy of Biologics in Patients With Moderate-to-Severe, Uncontrolled Asthma and Nasal Polyps
    Peters, Anju
    Han, Joseph
    Goeckner, Bryon
    Lindsley, Andrew
    Megally, Ayman
    Spahn, Joseph
    Ambrose, Christopher
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB100 - AB100
  • [48] Effectiveness and Safety Studies of Omalizumab in Children and Adolescents With Moderate-To-Severe Asthma
    Cheng, Lu
    Yang, Tianrui
    Ma, Xiang
    Han, Yuling
    Wang, Yongtai
    JOURNAL OF PHARMACY PRACTICE, 2023, 36 (02) : 370 - 382
  • [49] Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization
    Corren, Jonathan
    Hanania, Nicola A.
    Busse, William W.
    Sher, Lawrence D.
    Altincatal, Arman
    Hardin, Megan
    Mannent, Leda P.
    Amin, Nikhil
    Lederer, David J.
    Soler, Xavier
    Jacob-Nara, Juby A.
    Rowe, Paul J.
    Deniz, Yamo
    CLINICAL AND EXPERIMENTAL ALLERGY, 2023, 53 (10): : 1020 - 1030
  • [50] Characterizing patients with moderate-to-severe asthma with preserved small airway function
    Chan, Rory
    Lipworth, Brian
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 132 (01) : 93 - 95